title: Pseudomonas aeruginosa quorum-sensing signal molecule N-(3-oxododecanoyl)-L-homoserine lactone inhibits expression of P2Y receptors in cystic fibrosis tracheal gland cells.
abstract: ATP and UTP have been proposed for use as therapeutic treatment of the abnormal ion transport in the airway epithelium in cystic fibrosis (CF), the most characteristic feature of which is permanent infection by Pseudomonas aeruginosa. As for diverse gram-negative bacteria, this pathogenic bacterium accumulates diffusible N-acylhomoserine lactone (AHL) signal molecules, and when a threshold concentration is reached, virulence factor genes are activated. Human submucosal tracheal gland serous (HTGS) cells are believed to play a major role in the physiopathology of CF. Since ATP and UTP stimulate CF epithelial cells through P2Y receptors, we sought to determine whether CF HTGS cells are capable of responding to the AHLs N-butanoyl-L-homoserine lactone (BHL), N-hexanoyl-L-homoserine lactone (HHL), N-(3-oxododecanoyl)-L-homoserine lactone (OdDHL), and N-(3-oxohexanoyl)-L-homoserine lactone (OHHL), with special reference to P2Y receptors. All AHLs inhibited ATP- and UTP-induced secretion by CF HTGS cells. The 50% inhibitory concentrations were as high as 10 and 5 microM for BHL and HHL, respectively, but were only 0.3 and 0.4 pM for OdDHL and OHHL, respectively. Furthermore, all AHLs down-regulated the expression of the P2Y2 and P2Y4 receptors. Ibuprofen and nordihydroguaiaretic acid were able to prevent AHL inhibition of the responses to nucleotides, but neither dexamethasone nor indomethacin was able to do this. These data indicate that AHLs may alter responsiveness to ATP and UTP by CF HTGS cells and suggest that, in addition to ATP and/or UTP analogues, ibuprofen may be of use for a combinational pharmacological therapy for CF.
authors.affiliation: Groupe de Recherche sur les Glandes Exocrines, Faculté de Médecine, 13385 Marseille 05, France.
authors.forename: A
authors.initials: A
authors.lastname: Saleh
authors.forename: C
authors.initials: C
authors.lastname: Figarella
authors.forename: W
authors.initials: W
authors.lastname: Kammouni
authors.forename: S
authors.initials: S
authors.lastname: Marchand-Pinatel
authors.forename: A
authors.initials: A
authors.lastname: Lazdunski
authors.forename: A
authors.initials: A
authors.lastname: Tubul
authors.forename: P
authors.initials: P
authors.lastname: Brun
authors.forename: M D
authors.initials: MD
authors.lastname: Merten
mesh_terms: D015107:4-Butyrolactone / Q000031:analogs & derivatives* / Q000633:toxicity; D002460:Cell Line; D003550:Cystic Fibrosis / Q000150:complications*; D006714:Homoserine / Q000031:analogs & derivatives; D006801:Humans; D007052:Ibuprofen / Q000494:pharmacology; D011550:Pseudomonas aeruginosa / Q000472:pathogenicity*; D058919:Purinergic P2 Receptor Antagonists; D012333:RNA, Messenger / Q000032:analysis; D018048:Receptors, Purinergic P2 / Q000235:genetics; D058473:Receptors, Purinergic P2Y2; D014132:Trachea / Q000187:drug effects*
chemical_list: C109860:N-(3-oxododecanoyl)homoserine lactone; C546385:P2RY2 protein, human; D058919:Purinergic P2 Receptor Antagonists; D012333:RNA, Messenger; D018048:Receptors, Purinergic P2; D058473:Receptors, Purinergic P2Y2; C104749:purinoceptor P2Y4; D006714:Homoserine; D015107:4-Butyrolactone; D007052:Ibuprofen